# EN3285 for the Prevention or Delay of Oral Mucositis in Patients With Head and Neck Cancer

> **NCT00574860** · PHASE3 · TERMINATED · sponsor: **Endo Pharmaceuticals** · enrollment: 240 (actual)

## Conditions studied

- Oral Mucositis
- Head and Neck Cancer

## Interventions

- **DRUG:** EN3285
- **DRUG:** Placebo
- **OTHER:** Standard of care

## Key facts

- **NCT ID:** NCT00574860
- **Lead sponsor:** Endo Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-12
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 240 (ACTUAL)
- **Why stopped:** Additional research
- **Last updated:** 2013-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00574860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00574860, "EN3285 for the Prevention or Delay of Oral Mucositis in Patients With Head and Neck Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00574860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*